Stereotaxis (STXS) Projected to Post Earnings on Monday

Stereotaxis (NYSEAMERICAN:STXS) is projected to announce its Q4 2025 results after the market closes on Monday, March 9th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $9.24 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 9, 2026 at 4:30 PM ET.

Stereotaxis Stock Performance

Shares of NYSEAMERICAN STXS opened at $2.05 on Friday. Stereotaxis has a fifty-two week low of $1.54 and a fifty-two week high of $3.59. The stock has a fifty day moving average of $2.32 and a 200-day moving average of $2.59. The stock has a market cap of $191.31 million, a PE ratio of -7.32 and a beta of 1.38.

Institutional Investors Weigh In On Stereotaxis

Hedge funds have recently added to or reduced their stakes in the stock. WealthPLAN Partners LLC purchased a new position in shares of Stereotaxis in the 4th quarter worth $29,000. BNP Paribas Financial Markets increased its position in Stereotaxis by 106.5% during the third quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock valued at $36,000 after acquiring an additional 5,910 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Stereotaxis in the third quarter valued at about $38,000. HRT Financial LP purchased a new position in Stereotaxis in the fourth quarter worth about $42,000. Finally, Moneta Group Investment Advisors LLC bought a new stake in shares of Stereotaxis during the 3rd quarter valued at about $43,000. 45.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

STXS has been the topic of several analyst reports. Roth Mkm reissued a “buy” rating and issued a $4.00 target price on shares of Stereotaxis in a report on Wednesday, November 12th. Citigroup initiated coverage on Stereotaxis in a report on Tuesday, December 16th. They set an “outperform” rating for the company. Finally, Citizens Jmp initiated coverage on Stereotaxis in a research report on Tuesday, December 16th. They issued a “market outperform” rating and a $4.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $4.00.

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.